Sangamo Therapeutics (SGMO) Misses Q2 EPS by 2c

Sangamo Therapeutics (NASDAQ: SGMO) reported Q2 EPS of ($0.33), $0.02 worse than the analyst estimate of ($0.31). Revenue for the quarter came in at $27.9 million versus the consensus estimate of $26.48 million.

Cash, cash equivalents and marketable securities as of June 30, 2021 were $578.9 million compared to $692.0 million as of December 31, 2020.

GUIDANCE:

Guidance for 2021 Reiterated (initial guidance provided on February 24, 2021)

On a GAAP basis, we expect total operating expenses, including non-cash stock-based compensation expenses, to be in the range of approximately $285 million to $305 million for the year ended December 31, 2021.

On a non-GAAP basis, we expect total operating expenses, excluding estimated non-cash stock-based compensation expense of approximately $30 million, to be in the range of approximately $255 million to $275 million for the year ended December 31, 2021.

For earnings history and earnings-related data on Sangamo Therapeutics (SGMO) click here.

You May Also Be Interested In

• Blue Owl leads $2.4 billion debt deal for Iren data center
• HealthEquity (HQY) Tops Q2 EPS by 5c ; Offers Guidance
• Autodesk (ADSK) Tops Q2 EPS by 18c, Beats on Revenue; Offers FY27 EPS Guidance